LifeVantage Corporation (Nasdaq: LFVN) reported revenue of USD 48.9 million for the second quarter (Q2) ended December 31, 2025, representing a decrease of 27.8%. Revenue in the Americas declined 32.6%, while revenue in the Asia/Pacific & Europe region was down 2.1%. Net income per diluted share for Q2 was USD 0.02. Adjusted earnings per diluted share were USD 0.15, and adjusted EBITDA was USD 3.9 million. During the quarter, LifeVantage faced challenging competitive dynamics in the weight loss market following the October 2024 launch of its MindBody GLP-1 System. The company noted that the growth trajectory of MindBody has changed but reiterated its commitment to the product, describing it as a scientifically validated natural weight loss solution. Additionally, LifeVantage highlighted momentum in its LoveBiome portfolio, with several new product launches planned over the coming quarters and intentions to expand into new international markets as part of its growth strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeVantage Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9648993) on February 04, 2026, and is solely responsible for the information contained therein.